@prefix this: <http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo> .
@prefix sub: <http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_13884> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_13884>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00343>;
    a rdf:Statement;
    rdfs:label "\"Diltiazem hydrochloride injection is contraindicated in:    Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker.  Patients with second- or third-degree AV block except in the presence of functioning ventricular pacemaker.  Patients with severe hypotension or cardiogenic shock.  Patients who have demonstrated hypersensitivity to the drug.  Intravenous diltiazem and intravenous beta-blockers should not be administered together or in close proximity (within a few hours).  Patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in WPW syndrome or short PR syndrome. As with other agents which slow AV nodal conduction and do not prolong the refractoriness of the accessory pathway (eg, verapamil, digoxin), in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially life-threatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection. As such, the initial use of diltiazem hydrochloride injection should be, if possible, in a setting where monitoring and resuscitation capabilities, including DC cardioversion/defibrillation, are present (see    OVERDOSAGE Patients with ventricular tachycardia. Administration of other calcium channel blockers to patients with wide complex tachycardia (QRS >= 0.12 seconds) has resulted in hemodynamic deterioration and ventricular fibrillation. It is important that an accurate pretreatment diagnosis distinguish wide complex QRS tachycardia of supraventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection.\"";
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00343> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "GM1ebHORQSOLl0aXAdpMD9ZSDIBqY6ZVfNwWF1g37P6NzKhLxzAyywrpzAFG4/KbSCbRaBX/UzBhDAEMqh6H3dC1D+bMZ7JNj0NFtzWrJxVgbP336vDODnxNeOZ2B9EYjPLcxAg8yyG43/T4RSt2Vto3p5IfVUcFZwhNJUIuT0M=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-23T12:31:18.871+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}